Skip to main content

Market Overview

Morgan Stanley's Positive Comments On Bristol-Myers Squibb

Share:

In a report published Monday, Morgan Stanley analyst David Risinger and his team reiterated an Overweight rating on Bristol-Myers Squibb Co (NYSE: BMY) after the National Comprehensive Cancer Network (NCCN) updated its guidelines for the treatment of Non-Small Cell Lung Cancer (NSCLC) to include Opdivo in second-line non-squamous and squamous NSCLC.

According to the analysts, this is significant news because the company “has not yet filed with the FDA for non-squamous approval.” Even further, the NCCN said it “does not recommend testing for PD-L1, because many patients with metastatic NSCLC benefit from [Opdivo].”

These recommendations are based on the results of CheckMate-057 for non-squamous NSCLC (Category2A, mid-level evidence generates uniform consensus at the NCCN regarding intervention) and CheckMate-017 for squamous NSCLC (Category1, high-level evidence generates uniform consensus at the NCCN).

Related Link: Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers

Following the recommendation, however, Morgan Stanley maintains its Opdivo sales estimates of $1.1 billion for 2015, and $9.7 billion through 2020.

Shares of Bristol-Myers Squibb rose 0.2 percent on Monday afternoon and are up 11.69 percent year-to-date versus a 1.21 percent gain for the S&P 500.

Other Street Takes

Other analysts have also commented on the stock of late.

Credit Suisse sees the stock as the best in its class, and has a $75.00 price target set. Berenberg recently initiated coverage with a Hold rating and a $70.00 price target, while Deutsche Bank maintains a Hold as well, although its price target stands at $65.00.

Morgan Stanley rates the stock as Overweight, and sees the price escalating to $80.00.

Latest Ratings for BMY

DateFirmActionFromTo
Apr 2021Truist SecuritiesUpgradesHoldBuy
Nov 2020Societe GeneraleUpgradesHoldBuy
Nov 2020BernsteinReinstatesMarket Perform

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Health Care Price Target Reiteration Analyst Ratings General

Latest Ratings

StockFirmActionPT
DALJP MorganMaintains63.0
ALKJP MorganMaintains104.0
UALJP MorganMaintains58.0
SPGIBMO CapitalMaintains428.0
INFOBMO CapitalMaintains110.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com